Key Highlights

  • Alnylam Pharmaceuticals (NASDAQ:ALNY) was trading up 6.91% at USD 167.47 on Friday, November 13, 2026, in market data, and no company announcement dated November 12 or 13 explaining the move was found.
  • The board authorized a USD 1 billion share repurchase on November 4, 2026, with about USD 500 million expected by the end of 2026 and the remainder during 2027.
  • Third-quarter total net product revenues were USD 1,292 million, up 52% from USD 851 million, while GAAP Diluted Earnings per Share of USD 15.72 included a USD 1.9 billion tax benefit.
  • Guidance for 2026 total net product revenues of USD 4.7 billion to USD 5.1 billion was reiterated, and cash and marketable securities stood at USD 3.6 billion on September 30, 2026.

Buyback and an Executive Exit Frame the Week

No company announcement explaining Friday's move was found, so the most recent verified news comes from earlier in November. On November 4, 2026, Alnylam Pharmaceuticals (NASDAQ:ALNY) said its board authorized repurchases of up to USD 1 billion of common stock, with about USD 500 million planned by the end of 2026 and the rest during 2027, subject to market conditions. The company said the current share price does not fully reflect its intrinsic value. The same release said Chief Commercialization Officer Tolga Tanguler will depart, with a search for a successor under way. A buyback shrinks the share count but does not change earnings by itself. A published headline also cited a fresh 52-week low after the October 29 results; that is single-source and unconfirmed.

Revenue Up 52% but a Tax Benefit Inflates the Earnings Figure

Alnylam reported third-quarter results on October 29, 2026. Total net product revenues were USD 1,292 million, up 52% from USD 851 million, and AMVUTTRA, its transthyretin amyloidosis medicine, contributed USD 1,130 million, up 65%. Total revenues were USD 1,458 million, up 17%. GAAP Net Income was USD 2,167 million, or USD 15.72 per diluted share, but it includes a USD 1.9 billion income tax benefit from releasing valuation allowances on US deferred tax assets, so it is not a clean read of operating profit. Non-GAAP diluted EPS was USD 16.26. The company reiterated its 2026 outlook for total net product revenues of USD 4.7 billion to USD 5.1 billion.

Cemdisiran Decision and Trial Milestones Still Ahead

The next dated catalysts are regulatory and clinical. The company said the target action date for cemdisiran in generalized myasthenia gravis is November 2026, with Regeneron advancing the program, so that decision is upcoming and not yet verified as issued. Enrollment in the TRITON-CM study of nucresiran in ATTR cardiomyopathy was raised from 1,750 to about 2,250 patients, and a launch by 2030 is still expected if data and approval are positive. Phase 1 data for ALN-6400 are due at the December 2026 hematology meeting. Risks include slower AMVUTTRA uptake, access and pricing policy, and trial delays. A single-session move of 6.91% can fade.

Where Things Stand

Alnylam Pharmaceuticals (NASDAQ:ALNY) is up 6.91% on Friday without a company announcement that explains it, so the gain looks more like a rebound after a weak stretch than a response to new fundamentals. What is verified is a USD 1 billion buyback authorization, reiterated 2026 guidance and product Revenue growth of 52%. What is not verified is any link between the buyback and today's gain. Watch the cemdisiran action date, the pace of repurchases and the December data.